Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.gov public full text Public Domain

Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation

Abramson Cancer Center at Penn Medicine · 2009
ClinicalTrials.gov · Datasets · License: Public Domain · 2009
Open Source ↗
graft-versus-host-diseasehematopoietic-stem-cell-transplantation
This study investigates the effectiveness and safety of Maraviroc (an oral medication given twice daily given in addition to the standard GVHD prophylaxis) in preventing Graft versus Host Disease (GVHD) in patients undergoing non-myeloablative allogeneic stem-cell transplantation (SCT). Subjects will receive Maraviroc bid (in addition to standard GVHD prophylaxis) beginning after the last dose of the chemotherapy conditioning regimen until day 30 after stem-cell infusion.
Conceptio Open Archive

Analyze & explore related research in Conceptio

Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.

This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 843975
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive